FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Veterinary ophthalmology2021; 25(2); 173-179; doi: 10.1111/vop.12957

Effects of 0.0015% preservative-free tafluprost on the equine eye.

Abstract: The purpose of this study was to determine the effects and potential side effects of topical preservative-free (PF) tafluprost 0.0015% in ophthalmologically normal horses. Methods: Five adult grade horses. Methods: One of the eyes of each horse was randomly chosen as the "treatment" eye, and consequently, the contralateral eye served as the "control." A single dose of PF tafluprost 0.0015% (0.2 mL) was instilled in the treated eye of each horse. Intraocular pressure (IOP), Schirmer's tear test (STT) levels of each eye, and an ophthalmic examination were performed at T0 (baseline), T30, T120, T24 h, and T48 h. Results: The mean IOP values of the treated eyes at baseline (T0), T30, T120, T24 h, and T48 h were 25.4 ± 4.8 mmHg, 21.2 ± 1.92 mmHg, 15.20 ± 2.48 mmHg, 18.40 ± 1.51 mmHg, and 24.60 ± 1.94 mmHg, respectively. Significant differences were observed between the mean baseline IOP level and the T120 and T24 h time points (p = .001 and p = .009). The mean STT levels at each time point showed insignificant fluctuations during the study (p = .140). Adverse effects such as chemosis and episcleral injection were observed 30 min after the instillation of tafluprost 0.0015% (T30). Blepharospasm and conjunctival hyperemia were observed 120 min (T120) after the administration of the medication. Conclusions: Tafluprost 0.0015% showed potential in reducing IOP, but due to its local side effects, it is not a good candidate for management of glaucoma in horses. Tafluprost did not notably affect STT.
© 2021 American College of Veterinary Ophthalmologists.
Get Full Text
Publication Date: 2021-11-22 PubMed ID: 34806805DOI: 10.1111/vop.12957Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article focuses on evaluating the impacts and possible side effects of using the topical preservative-free drug tafluprost 0.0015% in horses with no ophthalmologic issues. The experiment concluded that while tafluprost effectively lowered intraocular pressure, it is not suitable for glaucoma management in horses due to its local side effects.

Study Overview

  • The study was designed to determine the effects of tafluprost 0.0015% on healthy horses and assess any potential side effects.
  • Five adult horses were enlisted in the study.
  • A ‘treatment’ and a ‘control’ eye were designated for each animal — the treatment eye received a single dose of tafluprost, and the other eye was kept intact as a control.
  • Intraocular pressure (IOP), Schirmer’s tear test (STT) levels, and ophthalmic examination were conducted at various intervals: baseline (T0), after 30 minutes (T30), 2 hours (T120), 24 hours (T24 h), and 48 hours (T48 h).

Results

  • Post tafluprost administration, IOP levels exhibited altered values at T0, T30, T120, T24 h, and T48 h.
  • Significant reduction in IOP levels was discerned at T120 and T24 h, compared to the baseline.
  • STT levels didn’t fluctuate much during the study, thus underlining that tafluprost doesn’t significantly affect STT.
  • Side effects such as chemosis (eye swelling) and episcleral injection (redness or inflammation) became apparent after 30 minutes of administering tafluprost.
  • Blepharospasm (forced blinking or squeezing) and conjunctival hyperemia (excessive blood flow in the conjunctiva) surfaced after 2 hours of administration.

Conclusions

  • Despite its efficiency in reducing IOP, harmful local side effects limit the application of tafluprost 0.0015% for managing glaucoma in horses.
  • The study also concluded that tafluprost doesn’t significantly affect STT.

Cite This Article

APA
Azimpour S, Emami Alagha H, Faghihi H, Rajaei SM, Shokoohimand A. (2021). Effects of 0.0015% preservative-free tafluprost on the equine eye. Vet Ophthalmol, 25(2), 173-179. https://doi.org/10.1111/vop.12957

Publication

Veterinary ophthalmology
ISSN: 1463-5224
NlmUniqueID: 100887377
Country: England
Language: English
Volume: 25
Issue: 2
Pages: 173-179

Researcher Affiliations

Azimpour, Saeed
  • Department of Veterinary Medicine, Babol Branch, Islamic Azad University, Babol, Iran.
Emami Alagha, Hannah
  • Department of Clinical Sciences, College of Veterinary Medicine, Islamic Azad University, Karaj Branch, Alborz, Iran.
Faghihi, Houman
  • Ophthalmology Section, Negah Veterinary Centre, Tehran, Iran.
  • Department of Clinical Sciences, Faculty of Veterinary Specialized Sciences, Islamic Azad University, Science and Research Branch, Tehran, Iran.
Rajaei, Seyed Mehdi
  • Department of Clinical Sciences, College of Veterinary Medicine, Islamic Azad University, Karaj Branch, Alborz, Iran.
  • Ophthalmology Section, Negah Veterinary Centre, Tehran, Iran.
Shokoohimand, Armin
  • Ophthalmology Section, Negah Veterinary Centre, Tehran, Iran.
  • Department of Clinical Sciences, Faculty of Veterinary Specialized Sciences, Islamic Azad University, Science and Research Branch, Tehran, Iran.

MeSH Terms

  • Animals
  • Antihypertensive Agents / therapeutic use
  • Horse Diseases / chemically induced
  • Horse Diseases / drug therapy
  • Horses
  • Intraocular Pressure
  • Ocular Hypertension / chemically induced
  • Ocular Hypertension / veterinary
  • Prostaglandins F / pharmacology
  • Prostaglandins F / therapeutic use
  • Tonometry, Ocular / veterinary

References

This article includes 26 references
  1. Michau TM. Equine Glaucoma. Vet Clin North Am Equine Pract 2017;33(3):519-540.
    doi: 10.1016/j.cveq.2017.07.005google scholar: lookup
  2. Plummer CE. Equine ophthalmology. In: Gelatt KN, ed. Veterinary Ophthalmology. 6th ed. John Wiley & Sons; 2021:1841-1981: chap 29.
  3. Thomasy SM, Lassaline M. Equine glaucoma: Where are we now?. Equine Vet Educ 2015;27(8):420-429.
    doi: 10.1111/eve.12370google scholar: lookup
  4. Sedacca K, Samuelson D, Lewis P. Examination of the anterior uveoscleral pathway in domestic species. Vet Ophthalmol 2012;15:1-7.
    doi: 10.1111/j.1463-5224.2011.00914.xgoogle scholar: lookup
  5. Wilkie DA. Equine glaucoma: state of the art. Equine Vet J 2010;42(S37):62-68.
    doi: 10.1111/j.2042-3306.2010.tb05637.xgoogle scholar: lookup
  6. Pizzirani S. Definition, classification, and pathophysiology of canine glaucoma. Vet Clin North Am Small Anim Pract 2015;45(6):1127-1157.
    doi: 10.1016/j.cvsm.2015.06.002google scholar: lookup
  7. Annear MJ, Gemensky-Metzler AJ, Wilkie DA. Uveitic glaucoma in the horse. Equine Vet Educ 2012;24(2):97-105.
    doi: 10.1111/j.2042-3292.2011.00310.xgoogle scholar: lookup
  8. Wilkie DA, Gemensky-Metzler AJ, Lassaline M, Brooks DE. Glaucoma. In: Gilger BC, ed. Equine Ophthalmology. , 3rd ed. Wiley Blackwell; 2017:453-468.
  9. Willis AM, Diehl KA, Hoshaw-Woodard S, Kobayashi I, Vitucci MP, Schmall LM. Effects of topical administration of 0.005% latanoprost solution on eyes of clinically normal horses. Am J Vet Res 2001;62(12):1945-1951.
    doi: 10.2460/ajvr.2001.62.1945google scholar: lookup
  10. Konstas AGP, Quaranta L, Katsanos A. Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension. Br J Ophthalmol 2013;97(12):1510-1515.
    doi: 10.1136/bjophthalmol-2012-303026google scholar: lookup
  11. Takagi Y, Nakajima T, Shimazaki A. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp Eye Res 2004;78(4):767-776.
    doi: 10.1016/j.exer.2003.12.007google scholar: lookup
  12. Kwak J, Kang S, Lee ER. Effect of preservative-free tafluprost on intraocular pressure, pupil diameter, and anterior segment structures in normal canine eyes. Vet Ophthalmol 2017;20(1):34-39.
    doi: 10.1111/vop.12341google scholar: lookup
  13. Giannico AT, Lima L, Shaw GC, Russ HHA, Froes TR, Montiani-Ferreira F. Effects of prostaglandin analogs on blood flow velocity and resistance in the ophthalmic artery of rabbits. Arq Bras Oftalmol 2016;79(1):33-36.
    doi: 10.5935/0004-2749.20160010google scholar: lookup
  14. Izumi N, Nagaoka T, Sato E. Short-term effects of topical tafluprost on retinal blood flow in cats. J Ocul Pharmacol Ther 2008;24(5):521-526.
    doi: 10.1089/jop.2007.0065google scholar: lookup
  15. Davidson HJ, Pinard CL, Keil SM, Brightman AH, Sargeant JM. Effect of topical ophthalmic latanoprost on intraocular pressure in normal horses. Vet Ther Spring 2002;3(1):72-80.
  16. FDA. Latanoprost ophthalmic solution. Accessed January 22, 2021.
  17. FDA. ZIOPTAN prescribing information. Accessed October 11, 2020.
  18. Miyake K, Ota I, Maekubo K, Ichihashi S, Miyake S. Latanoprost accelerates disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema in early postoperative pseudophakias. Arch Ophthalmol 1999;117(1):34-40.
    doi: 10.1001/archopht.117.1.34google scholar: lookup
  19. Sorkhabi R, Alipanahi R, Eftakhari-Milani A, Ghojazadeh L. The influence of topical diclofenac sodium on the ocular hypotensive effect of latanoprost in glaucoma patients. J Glaucoma 2011;20(4):240-243.
    doi: 10.1097/ijg.0b013e3181e07933google scholar: lookup
  20. Yousufzai SYK, Ye ZHI, Abdel-Latif AA. Prostaglandin F2αand its analogs induce release of endogenous prostaglandins in iris and ciliary muscles isolated from cat and other mammalian species. Exp Eye Res 1996;63(3):305-310.
    doi: 10.1006/exer.1996.0119google scholar: lookup
  21. Neumann R, Jabbur NS, Vickers F, Foster SC. Topical diclofenac sodium, dexamethasone and placebo compared in a model of immunogenic uveitis in rabbits. Ocul Immunol Inflamm 2009;1(1-2):87-98.
    doi: 10.3109/09273949309086543google scholar: lookup
  22. Tofflemire K, Whitley EM, Allbaugh R. Effect of topical ophthalmic latanoprost 0.005% solution alone and in combination with diclofenac 0.1% solution in healthy horses: a pilot study. Vet Ophthalmol 2017;20(5):398-404.
    doi: 10.1111/vop.12439google scholar: lookup
  23. Shokoohimand A, Arfaee F, Asghari A, Khaksar E. Effects of topical administration of tafluprost and combination of tafluprost and timolol or tafluprost and betaxolol on Schirmer tear test, intraocular pressure, and pupil size in clinically healthy dogs. Int Ophthalmol 2020;40(10):2585-2592.
    doi: 10.1007/s10792-020-01439-9google scholar: lookup
  24. Yamagishi R, Aihara M, Araie M. Neuroprotective effects of prostaglandin analogues on retinal ganglion cell death independent of intraocular pressure reduction. Exp Eye Res 2011;93(3):265-270.
    doi: 10.1016/j.exer.2011.06.022google scholar: lookup
  25. Bull ND, Johnson TV, Welsapar G, DeKorver NW, Tomarev SI, Martin KR. Use of an adult rat retinal explant model for screening of potential retinal ganglion cell neuroprotective therapies. Investig Opthalmol Vis Sci 2011;52(6):3309.
    doi: 10.1167/iovs.10-6873google scholar: lookup
  26. Iida Y, Akagi T, Nakanishi H. Retinal blood flow velocity change in parafoveal capillary after topical tafluprost treatment in eyes with primary open-angle glaucoma. Sci Rep 2017;7(1).
    doi: 10.1038/s41598-017-05258-4google scholar: lookup

Citations

This article has been cited 0 times.
Subscribe to our newsletter
Join 99,911 horse owners like you who receive our email updates on horse health and nutrition.